INTERCEPT PHARMACEUTICALS, INC. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Revenue
Product
License
Total revenue

Operating expenses:
Cost of sales
Selling, general and administrative
Research and development
Restructuring
Total operating expenses
Operating loss
Other (expense) income:
Interest expense
(Loss) gain on extinguishment of debt
Other income, net
Total other (expense) income, net
Loss from continuing operations
Income (loss) from discontinued operations, net of income taxes
Net income (loss)
Net income (loss) per common and potential common share (basic and diluted):
Basic and diluted
Basic and diluted
Net loss from continuing operations, Basic (in dollars per share)
Net loss from continuing operations, Diluted (in dollars per share)
Net income (loss) from discontinued operations, Basic (in dollars per share)
Net income (loss) from discontinued operations, Diluted (in dollars per share)
Net income (loss), Basic (in dollars per share)
Net income (loss), Diluted (in dollars per share)
Weighted average common and potential common shares outstanding:
Basic (in shares)
Diluted (in shares)

Comments